![]() | ![]() |
Formats:
|
||||||||||||||||||||
Recognition of Staphylococcus aureus-derived peptidoglycan (PGN) but not intact bacteria is mediated by CD14 in microglia Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot 846, Little Rock, AR 72205, United States * Corresponding author. Tel.: +1 501 526 6348; fax: +1 501 526 6756.E-mail address: KielianTammyL/at/uams.edu (T. Kielian) The publisher's final edited version of this article is available at J Neuroimmunol. See other articles in PMC that cite the published article.Abstract Recognition of Staphylococcus aureus and its cell-wall component peptidoglycan (PGN) by microglia is mediated, in part, by Toll-like receptor 2 (TLR2). However, the pattern recognition receptor (PRR) CD14 can also bind PGN and enhance TLR2-mediated signaling in macrophages, suggesting a similar phenomenon might occur in microglia. To assess the functional significance of CD14 on microglial activation, we evaluated the responses of primary microglia isolated from CD14 knockout (KO) and wild type (WT) mice. PGN-dependent microglial activation was partially CD14-dependent as demonstrated by the attenuated expression of TNF-α, macrophage inflammatory protein-2 (MIP-2/CXCL2), and the soluble PRR pentraxin-3 in CD14 KO microglia compared to WT cells. In contrast, microglial responses to intact S. aureus occurred primarily via a CD14-independent manner. Collectively, these findings reveal the complex nature of gram-positive bacterial recognition by microglia, which occurs, in part, via CD14. Keywords: CD14, Microglia, S. aureus, Peptidoglycan, Lipopolysaccharide, Central nervous system, Pentraxin-3 1. Introduction Microglia represent one effector arm of innate immunity in the central nervous system (CNS) parenchyma as evident by their roles in pathogen recognition and antigen presentation (Aloisi, 2001; Hanisch, 2002). As such, microglia are uniquely poised to provide an initial line of protection against invading microorganisms into CNS prior to leukocyte infiltration. The defense function of microglia is mainly provided by the expression of pattern recognition receptors (PRR) capable of recognizing pathogen-associated molecular patterns (PAMPs) (Akira and Hemmi, 2003; Husemann et al., 2002; Marzolo et al., 1999). PAMPs are defined as invariant molecular motifs of bacteria, fungi, and viruses that are essential for pathogen survival and are conserved across broad subclasses of pathogens (Akira and Hemmi, 2003; Takeda et al., 2003). Studies have demonstrated that Toll-like receptors (TLR) are important for PAMP recognition, and microglia express the majority of TLRs identified to date (TLR1–9)(Bsibsi et al., 2002; Kielian et al., 2002, 2005; Laflamme et al., 2003; Olson and Miller, 2004), which, in theory, enables these cells to recognize a wide spectrum of PAMPs (Akira and Hemmi, 2003; Sieling and Modlin, 2002; Takeda et al., 2003). Recently, we reported the functional importance of TLR2 in mediating microglial activation in response to Staphylococcus aureus (S. aureus) and its cell wall component peptidoglycan (PGN) using primary microglia isolated from TLR2 knockout (KO) and wild-type (WT) mice (Kielian et al., 2005). Our results revealed that TLR2 is pivotal for PGN recognition and subsequent activation in microglia, as demonstrated by the attenuated expression of proinflammatory mediators in PGN-treated TLR2 KO microglia compared with WT cells. In contrast, the importance of this receptor in microglial responses to S. aureus was not as dramatic, indicating that in addition to TLR2, alternative receptors are responsible for recognizing intact bacteria (Kielian et al., 2005). CD14 is another PRR involved in PAMP recognition, and is found in two forms, namely membrane-bound (mCD14) and soluble CD14 (sCD14). Membrane-bound CD14 is expressed on cells of the myeloid lineage including microglia and macrophages (Becher et al., 1996; Kielian et al., 2002, 2005; Nadeau and Rivest, 2000; Saito et al., 2000; Tsan et al., 2001). It has been well established that mCD14 plays a pivotal role in enabling cells to recognize the gram-negative bacterial cell wall component lipopolysaccharide (LPS) (Dobrovolskaia and Vogel, 2002; Palsson-McDermott and O’Neill, 2004). Since mCD14 is a glycosylphosphatidyl inositol (GPI)-anchored receptor, it requires interaction with TLR4 to transduce activation signals in response to LPS (Dobrovolskaia and Vogel, 2002; Fitzgerald et al., 2004; Haziot et al., 1988; Palsson-McDermott and O’Neill, 2004). However, recent evidence also supports a role for mCD14 in the recognition of gram-positive PAMPs such as PGN and lipoteichoic acid (Cleveland et al., 1996; Dziarski et al., 2000a; Gupta et al., 1996). With respect to gram-positive bacterial antigens, mCD14 is thought to interact with either TLR2/TLR1 or TLR2/TLR6 heterodimers to induce cell activation and subsequent effector functions (Henneke et al., 2001; Kielian et al., 2002; Manukyan et al., 2005; Schroder et al., 2003; Weber et al., 2003). Soluble CD14 can also bind both PGN and LPS (Dziarski, 2003; Gupta et al., 1996; Hailman et al., 1994); however, these complexes have disparate effects on cell activation in mCD14-negative cells. For example, sCD14-LPS complexes are capable of activating mCD14-negative cells (Cohen et al., 1995; Haziot et al., 1993), whereas sCD14-PGN aggregates are not active (Dziarski et al., 2000b; Jin et al., 1998). The reason(s) responsible for the differential effects of sCD14-LPS versus -PGN complexes on mCD14-negative cells remain unknown. With regard to mCD14-positive cells, sCD14-antigen aggregates act in an additive manner to enhance cell activation compared with each PAMP alone (Dziarski et al., 2000b; Hailman et al., 1996). S. aureus is one of the main pathogens of CNS parenchymal infection leading to the establishment of brain abscess (Kielian, 2004). However, the mechanisms by which S. aureus influences immune activation in the CNS remain to be fully defined. Previous studies from our laboratory have shown that both S. aureus and PGN enhance microglial PRR expression, which may serve to potentiate the antibacterial immune response in infected brain parenchyma prior to leukocyte infiltration (Kielian et al., 2002, 2005). In addition, upon exposure to S. aureus and PGN, microglia respond with the robust synthesis and release of numerous proinflammatory mediators as well as internalizing and killing S. aureus in vitro (Kielian et al., 2002, 2005). Although previous studies have demonstrated that PGN binds to CD14 and enhances TLR2-mediated signaling in macrophages (Iwaki et al., 2002; Koedel et al., 2003; Schwandner et al., 1999), the fundamental role of CD14 in S. aureus- and PGN-dependent microglial activation is not known. In the current study, we evaluated the relative importance of CD14 on S. aureus and PGN recognition using primary microglia isolated from CD14 KO and WT mice. Since fetal bovine serum (FBS) serves as a source of sCD14 and LPS binding protein (LBP), the latter of which facilitates the transfer of PGN to mCD14 (Cohen et al., 1995; Dziarski, 2003; Wright et al., 1990; Yang et al., 1994), we examined microglial activation in response to gram-positive stimuli under serum-free conditions to prevent any confounding effects of serum on the results obtained. The findings presented demonstrate that CD14 participates in PGN-dependent microglial activation, whereas responses to intact S. aureus are primarily CD14-independent. Collectively, these findings reveal the complex nature of gram-positive pathogen recognition by microglia which occurs, in part, via CD14. 2. Materials and methods 2.1. Primary microglia cell culture and reagents CD14 KO mice backcrossed for six generations (C57BL/ 6 background) were generously provided by Dr. Mason Freeman (Harvard Medical School, USA). Primary microglia were isolated from CD14 KO or WT C57BL/6 pups (Harlan Labs, Indianapolis, IN; 1–8 days of age) as previously described (Esen et al., 2004; Kielian et al., 2005). The purity of microglial cultures was evaluated by immunohistochemical staining using antibodies against CD11b (BD PharMingen, San Diego, CA) and glial fibrillary acidic protein (GFAP; DAKO Corp., Carpenteria, CA) to identify microglia and astrocytes, respectively. The purity of primary microglial cultures was routinely greater than 95%. Microglia were maintained in culture medium supplemented with 10% FBS (Kielian et al., 2004); however, for all of the experiments described herein, cells were plated and stimulated under serum-free conditions to rule out any potential confounding effects of sCD14 and LBP that are present in FBS on cell activation. Heat-inactivated S. aureus (strain RN6390, kindly provided by Dr. Ambrose Cheung, Dartmouth Medical School) was prepared as previously described (Kielian et al., 2002). PGN derived from S. aureus was obtained from Fluka (St. Louis, MO) and Escherichia coli O11:B1 LPS was from List Biological Laboratories (Campbell, CA). All non-LPS reagents and culture media were verified to have endotoxin levels <0.03 EU/ml as determined by Limulus amebocyte lysate assay (LAL; Associates of Cape Cod, Falmouth, MA). In addition, a phosphate assay (Pierce, Rockford, IL) was performed on the PGN stock to ensure reagent purity since commercial PGN preparations have been reported to be contaminated with LTA and bacterial DNA (Travassos et al., 2004), whereas PGN does not contain phosphate residues. The phosphate content of the PGN preparation used in this study was below the limit of detection, indicating that it was not contaminated with alternative microbial products. Unless otherwise indicated, heat-inactivated S. aureus (107 cfu/ml) PGN (10 μg/ml), and LPS (100 ng/ml) were added to microglial cultures at the final concentrations indicated, representing doses that were previously determined to be optimal for inducing maximal proinflammatory cytokine expression in microglia without any evidence of cytotoxicity (Kielian et al., 2004, 2005). 2.2. ELISA Comparisons in cytokine and chemokine expression between CD14 WT and KO primary microglia were performed using standard sandwich ELISA kits according to the manufacturer’s instructions (OptEIA mouse TNF-α, IL-12 p40, and IL-1β, BD PharMingen; DuoSet mouse MIP-2/CXCL2, R&D Systems, Minneapolis, MN). The level of sensitivity for all ELISAs was 15.6 pg/ml. 2.3. Cell viability assays To confirm that the observed changes in inflammatory mediator expression between CD14 WT and KO microglia were not due to differences in cell seeding densities or potential confounding proliferative effects, a standard MTT assay based upon the mitochondrial conversion of (3-[4,5-dimethylthiazol–2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) into formazan crystals was performed as previously described (Kielian et al., 2004). 2.4. Quantitative real-time RT-PCR (qRT-PCR) Total RNA from CD14 WT and KO primary microglia was isolated using the TriZol reagent and treated with DNAse1 (both from Invitrogen, Carlsbad, CA) prior to use in qRT-PCR studies. The experimental procedure was performed as previously described (Kielian et al., 2005). Briefly, TLR2, CD14, and GAPDH primers and TAMRA Taqman probes were designed as previously described (Esen et al., 2004; Kielian et al., 2005) and synthesized by Applied Biosystems (ABI, Foster City, CA). ABI Assays-on-Demand™ Taqman kits were utilized to examine microglial TLR9, pentraxin-3 (PTX3), and lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) expression. Comparisons in gene expression between CD14 WT and KO primary microglia were calculated after normalizing cycle thresholds against the ‘‘housekeeping’’ gene GAPDH and are presented as the fold-induction (2−ΔΔCt) value relative to unstimulated microglia. 2.5. Protein extraction and Western blotting Protein extracts were prepared and quantitated from both CD14 WT and KO primary microglia as previously described (Kielian et al., 2004). The effects of heat-inactivated S. aureus, PGN, and LPS on microglial CD14 and MyD88 protein expression were evaluated by Western blot analysis. Blots were probed using rabbit anti-mouse MyD88 (E-Biosciences, San Diego, CA) or rat anti-mouse CD14 antibodies (clone RMC5-3, BD Pharmingen) followed by a donkey anti-rabbit IgG-HRP conjugate (Jackson Immunoresearch, West Grove, PA). Duplicative blots were probed with a rabbit anti-actin polyclonal antibody (Sigma, St. Louis, MO) for normalization. Blots were developed using the ChemiGlow West substrate (Alpha Innotech, San Leandro, CA) and visualized by exposure to X-ray film. 2.6. Statistics Significant differences between experimental groups were determined using the unpaired Student’s t-test at the 95% confidence interval with Sigma Stat (SPSS Science, Chicago, IL). 3. Results 3.1. Effects of S. aureus and PGN on CD14 expression in primary microglia It is well established that CD14 is expressed on macrophages and plays an important role in the generation of immune responses to gram-negative bacteria (Dobrovolskaia and Vogel, 2002; Triantafilou and Triantafilou, 2002; Wright et al., 1990). However, recent studies have revealed that CD14 can also bind gram-positive bacterial components such as PGN and lipoteichoic acid (Cleveland et al., 1996; Dziarski, 2003; Dziarski et al., 2000a; Gupta et al., 1996). Since microglia represent the first line of defense against bacterial infections in the CNS parenchyma and modulating PRR expression may have implications on the extent of microglial antibacterial responses, the effects of S. aureus and PGN on CD14 protein expression in primary microglia was evaluated by Western blotting. Since serum contains sCD14 and LBP that are capable of augmenting cell responses to microbial stimuli (Cohen et al., 1995; Wright et al., 1990; Yang et al., 1994), the ability of S. aureus and PGN to modulate CD14 expression was evaluated in the absence of serum. Under these conditions, both S. aureus and PGN stimulation led to an increase in CD14 protein expression in primary WT microglia (Fig. 1
3.2. CD14 differentially regulates PGN and S. aureus recognition by microglia The functional role of mCD14 in LPS-related macrophage responses has been studied extensively and the signal transduction mechanisms in cooperation with TLR4 are well-defined (Dobrovolskaia and Vogel, 2002; Hailman et al., 1994; Palsson-McDermott and O’Neill, 2004; Takeda et al., 2003). However, the direct functional importance of CD14 in mediating microglial responses to gram-positive stimuli has not yet been examined. Therefore, we compared the responses of primary microglia isolated from CD14 KO and WT mice to intact S. aureus and PGN. The absence of CD14 expression in KO microglia was confirmed by both qRT-PCR (data not shown) and Western blot analysis (Fig. 1
Compared to TNF-α release, examination of chemokine expression in CD14 KO and WT microglia revealed slightly different requisites for CD14 in the responses of cells to various doses of S. aureus and PGN (Fig. 3
We have previously demonstrated that, unlike the majority of proinflammatory mediators examined, IL-12 p40 expression was significantly increased in S. aureus-stimulated TLR2 KO microglia compared to WT cells (Kielian et al., 2005). Since TLR2 and CD14 have been reported to cooperate in mediating macrophage activation in response to gram-positive stimuli (Medvedev et al., 1998; Schwandner et al., 1999; Yoshimura et al., 1999), we examined whether a similar phenomenon occurs in CD14 KO microglia. Similar to our findings with TLR2 KO microglia, IL-12 p40 production was consistently elevated in CD14 KO microglia in response to S. aureus compared to WT cells (Fig. 4
3.3. Modulation of CD14 KO microglial activation in response to bacterial stimuli is not due to defective MyD88 expression Upon LPS binding, CD14 physically interacts with TLR4 to initiate intracellular signaling since the former is GPI-anchored and lacks a cytoplasmic signaling domain (Dobrovolskaia and Vogel, 2002; Palsson-McDermott and O’Neill, 2004; Triantafilou and Triantafilou, 2002). In the case of gram-positive bacterial components, evidence suggests that CD14 can enhance TLR2-dependent signaling in macrophages (Harokopakis and Hajishengallis, 2005; Manukyan et al., 2005; Schroder et al., 2003). The majority of Toll-like receptors identified to date utilize a common signal transduction pathway with minor differences that appear to confer specificity in response to distinct ligands (Akira and Hemmi, 2003; Gantner et al., 2003; Takeda et al., 2003). MyD88 is a central player in the signal transduction pathways of the IL-1R, IL-18R, and TLRs (with the exception of TLR3), providing a bridge between the cytoplasmic domains of these receptors and IL-1R-associated kinase (IRAK) (Akira and Hemmi, 2003; Kawai and Akira, 2005; Takeda et al., 2003; Yamamoto et al., 2004). To determine the role of CD14 in regulating MyD88 expression in response to bacterial stimuli, we evaluated the levels of these proteins in both CD14 WT and KO microglia. Interestingly, constitutive levels of MyD88 protein were low in unstimulated CD14 KO microglia; however, following bacterial exposure MyD88 levels were enhanced in CD14 KO microglia (Fig. 5
3.4. Role of CD14 on the expression of alternative PRRs in microglia Recently we have demonstrated that responses to S. aureus were not abolished in TLR2 KO microglia, implying a role for alternative receptors in S. aureus recognition in these cells (Kielian et al., 2005). Although CD14, which has been shown to mediate macrophage activation in response to PGN and other gram-positive bacterial components (Cleveland et al., 1996; Dziarski et al., 1998; Kusunoki et al., 1995), was another logical candidate, in the present study we have shown that S. aureus activates microglia primarily via a CD14-independent manner. Therefore, to determine the effects of S. aureus on additional PRRs that could be responsible for bacterial recognition, we evaluated differences in pentraxin-3 (PTX3), lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and TLR9 expression in both CD14 KO and WT microglia using qRT-PCR. Both PTX3 and LOX-1 represent phagocytic PRRs that may be responsible for S. aureus uptake by microglia, whereas TLR9 may be important for inducing proinflammatory mediator production in response to non-methylated CpG DNA motifs contained within heat-inactivated bacteria. Alterations in microglial receptor expression following PGN stimulation were also evaluated to assess potential differential effects of the two bacterial stimuli. PTX3 is a secreted PRR that is produced by activated macrophages (Alles et al., 1994; Introna et al., 1996) and physically binds to several bacteria and fungi, implying an important role for PTX3 in the innate immune response (Garlanda et al., 2002; Mantovani et al., 2003). The expression of this PRR in microglia and the role of CD14-dependent signals in regulating PTX3 levels have not yet been reported, although a recent study has revealed that TLR2-dependent activation is important for modulating PTX3 levels in macrophages (Jeannin et al., 2005). The present study is the first report demonstrating PTX3 expression in primary microglia (Fig. 6A
Additional PRR candidates that could be involved in mediating microglial responses to S. aureus include scavenger receptors which represent a large class of cell surface molecules that recognize a wide array of both exogenous and endogenous ligands including PAMPs and modified low-density lipoproteins (Husemann et al., 2002; Peiser et al., 2002). Within this family we chose to investigate LOX-1 since this receptor has been reported to bind S. aureus directly (Shimaoka et al., 2001). LOX-1 mRNA expression was significantly elevated in response to both S. aureus and PGN (Fig. 7
Although studies have established that TLR2 is required for cellular responses to S. aureus (Akira and Hemmi, 2003; Kaisho and Akira, 2002), recent evidence has revealed that DNA can influence cellular activation by engaging the intracellular PRR TLR9 (Athman and Philpott, 2004; Dziarski, 2003; Hemmi et al., 2000). Intact S. aureus presents microglia with a complex milieu of antigens including DNA containing non-methylated CpG motifs, the only known bacterial ligand of TLR9, suggesting that S. aureus may induce immunological responses through this receptor. In the present study we have determined that TLR9 expression was differentially modulated by S. aureus and PGN. Specifically, the extent of TLR9 inhibition following microglial activation was significantly more pronounced in PGN-treated compared to S. aureus-treated cells, with the latter displaying a delayed increase in TLR9 mRNA levels at 24 h post-stimulation (Fig. 8
Collectively, the evaluation of additional PRRs indicates that CD14-dependent activation signals influence microglial PTX3 expression in response to PGN; however, the effects of S. aureus and PGN on LOX-1 and TLR9 expression are CD14-independent. The S. aureus-induced effects on LOX-1 and TLR9 expression may compensate for the loss of CD14 in KO microglia, thus explaining, in part, the inability to detect widespread differences in activation status between CD14 KO and WT cells in response to intact bacteria. 4. Discussion Pathogen recognition by cells of the myeloid lineage represents a first step towards initiating complex inflammatory reactions characteristic of innate immune responses. Although gram-positive pathogens are common etiologic agents of CNS bacterial infections (Mathisen and Johnson, 1997; Townsend and Scheld, 1998), the innate immune mechanisms elicited by these organisms in microglia still remain to be completely defined. In the CNS, microglia likely play an essential role in initiating innate immunity through their extensive expression of PRRs including TLRs and CD14 (Bsibsi et al., 2002; Dalpke et al., 2002, Kielian et al., 2002; Laflamme et al., 2001; Olson and Miller, 2004). Using primary microglia from CD14 KO and WT mice, we demonstrated that CD14 participates in PGN recognition by microglia. However, the residual levels of proinflammatory mediator expression detected in PGN-stimulated CD14 KO microglia indicate that CD14 cooperates with additional PRRs for maximal cellular activation. Indeed, the findings reported here are in close agreement with our recently published studies investigating the functional importance of TLR2 in PGN-dependent microglial activation, where the loss of TLR2 did not result in the complete ablation of proinflammatory mediator release from PGN-activated microglia (Kielian et al., 2005). Taken together, these findings suggest that TLR2 and CD14 may function cooperatively to mediate maximal microglial activation in response to S. aureus-derived PGN. Indeed, evidence to support the collaborative actions of TLR2 and CD14 in the recognition of gram-positive bacteria is provided by recent studies demonstrating that macrophage activation in response to group B streptococci (GBS) involves the coordinated efforts of both receptors (Medvedev et al., 1998; Yoshimura et al., 1999). Studies are underway to directly assess the cooperation between TLR2 and CD14 in regulating PGN-dependent microglial activation by examining primary microglia from TLR2/CD14 double KO mice. Although we were able to demonstrate that CD14 participates in LPS-dependent microglial activation presumably via its interactions with TLR4, it was evident that at higher antigen doses cell activation could begin to proceed via a CD14-independent manner. Indeed, the ability of high-dose LPS to activate macrophages through CD14/TLR4-independent pathways has been well established and may be a consequence of engaging lower affinity receptors under conditions of excess antigen (Haziot et al., 1999; Lynn et al., 1993; Perera et al., 1997). The identity of receptor(s) that may be responsible for mediating CD14-, and presumably TLR4-independent microglial activation in response to LPS are currently unknown. The finding that microglial responses to intact bacteria were not dramatically affected by the loss of CD14 suggests that microglia utilize alternative PRRs for S. aureus recognition. Indeed, recent evidence has revealed the existence of receptor cross-talk between TLRs and phagocytic receptors (Underhill and Gantner, 2004; Underhill and Ozinsky, 2002). For example, recent studies suggest that TLRs may regulate phagosome formation and maturation as well as modulate the transcription of some phagocytic receptors, while signaling via phagocytic receptors can also modulate TLR signaling (Underhill and Gantner, 2004). Relevant to the current study, through its ability to enhance TLR-dependent signaling, CD14 may also influence microglial activation by regulating the expression and/or activity of phagocytic PRRs. Although TLRs and CD14 are pivotal PRRs, they do not function directly as phagocytic receptors. This is supported by our findings where MyD88 KO microglia were still capable of phagocytizing heat-inactivated S. aureus (Kielian, unpublished observations) in addition to studies by others demonstrating that macrophages with a deletion of TLR2 or MyD88 were not capable of producing proinflammatory cytokines but were still able to internalize pathogens (Henneke et al., 2002; Underhill et al., 1999). To begin to investigate the potential involvement of alternative phagocytic PRRs in microglial responses to S. aureus, we examined the expression of the scavenger receptor LOX-1 and PTX3 in primary microglia. Our results represent the first evidence demonstrating that CD14-dependent signals are essential for maximal PTX3 expression in PGN-activated microglia. In addition, we have recently found that the PGN-induced increase in PTX3 expression is also attenuated in TLR2 KO microglia (Kielian, unpublished observations). Taken together, we suggest that CD14, possibly in cooperation with TLR2, induces PTX3 expression in primary microglia, which may result from the autocrine action of proinflammatory cytokines released from activated microglia following bacterial exposure. Interestingly, although our objective in examining PTX3 expression in microglia was to determine whether this soluble PRR may participate in the recognition event of intact bacteria, we found that S. aureus was not capable of augmenting microglial PTX3 expression. However, a definitive role for PTX3 in mediating microglial responses to S. aureus awaits the examination of cells from PTX3 KO animals. With regard to LOX-1, the expression of this phagocytic PRR was significantly increased in microglia following S. aureus exposure, suggesting that it may participate in bacterial recognition. Although we were unable to detect any significant differences in LOX-1 expression between CD14 KO and WT microglia, it is important to acknowledge that CD14-dependent signals may influence the subsequent extent of LOX-1-dependent phagocytosis by modulating constitutive LOX-1 activity. Therefore, definitive information regarding the potential functional cooperativity of LOX-1 with CD14 in mediating S. aureus-dependent microglial activation awaits the generation of LOX-1/CD14 double KO mice. It is well established that primary microglia respond to S. aureus and PGN with the robust production of proinflam-matory cytokines and chemokines, such as TNF-α, IL-1β, MIP-2, and MCP-1 (Kielian et al., 2002, 2005). In addition, we have recently reported that TLR2 is pivotal for proinflammatory cytokine production in response to PGN (Kielian et al., 2005), with the present study extending these findings to demonstrate a role for CD14 in this recognition event, possibly via receptor cooperation. However, one consistent finding that surfaced during the course of the current study and previous work with TLR2 KO microglia (Kielian et al., 2005) relates to the heightened release of IL-12 p40 by S. aureus activated KO microglia. Specifically, both CD14 and TLR2 KO microglia produced more IL-12 p40 in response to S. aureus compared with WT cells, suggesting that these receptors play an integral role in regulating IL-12 expression. Interestingly, IL-12 p40 levels were not elevated in either CD14 or TLR2 KO microglia in response to PGN, indicating that the influence of these PRRs on cytokine regulation is antigen-specific. These findings suggest that under normal conditions, TLR2 and CD14 may serve to regulate IL-12 p40 release by inducing suppressor cytokines and/or activating a direct suppressor pathway. Candidate molecules may include IL-10 and/or the suppressors of cytokine signaling (SOCS) proteins (Alexander and Hilton, 2004; Elliott and Johnston, 2004; Williams et al., 2004), possibilities that are currently under investigation in our laboratory. In conclusion, these results demonstrate that CD14 participates in regulating microglial proinflammatory mediator release in response to PGN. We have recently established that CD14 plays a functional role in dictating the ensuing CNS host immune response in a mouse model of S. aureus-induced experimental brain abscess. Specifically, CD14 appears to participate in regulating the release of select proinflammatory mediators as well as modulating blood–brain barrier permeability at the later stages of infection (Kielian, manuscript in preparation). However, despite these differences bacterial titers were not significantly different between CD14 KO and WT mice, indicating that alternative PRRs are responsible for controlling CNS bacterial burdens. Based upon the functional similarities in responses between CD14 and TLR2 KO microglia following PGN exposure, we propose that these receptors function in a multi-receptor complex to coordinate maximal proin-flammatory mediator production and PTX3 expression in microglia to facilitate pathogen recognition and phagocytosis in the infected CNS. Acknowledgments The authors would like to thank Dr. Mason Freeman for generously providing the CD14 KO mice, Dr. Paul Drew for critical review of the manuscript, and Patrick Mayes for excellent technical assistance. This work was supported by the NIH National Institute of Mental Health (RO1 MH65297) to T.K. and the National Institute of Neurological Disorders and Stroke supported Core facility at UAMS (P30 NS047546). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Glia. 2001 Nov; 36(2):165-79.
[Glia. 2001]Glia. 2002 Nov; 40(2):140-55.
[Glia. 2002]Immunol Lett. 2003 Jan 22; 85(2):85-95.
[Immunol Lett. 2003]Glia. 2002 Nov; 40(2):195-205.
[Glia. 2002]J Neurosci Res. 1999 Nov 1; 58(3):387-95.
[J Neurosci Res. 1999]J Neurosci Res. 1996 Aug 15; 45(4):375-81.
[J Neurosci Res. 1996]J Neuroimmunol. 2002 Sep; 130(1-2):86-99.
[J Neuroimmunol. 2002]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Neurosci. 2000 May 1; 20(9):3456-68.
[J Neurosci. 2000]Eur J Biochem. 2000 Jan; 267(1):37-45.
[Eur J Biochem. 2000]J Neuroinflammation. 2004 Aug 17; 1(1):16.
[J Neuroinflammation. 2004]J Neuroimmunol. 2002 Sep; 130(1-2):86-99.
[J Neuroimmunol. 2002]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Biol Chem. 2002 Jul 5; 277(27):24315-20.
[J Biol Chem. 2002]J Immunol. 2003 Jan 1; 170(1):438-44.
[J Immunol. 2003]J Neurochem. 2004 Feb; 88(3):746-58.
[J Neurochem. 2004]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Neurochem. 2004 Sep; 90(5):1163-72.
[J Neurochem. 2004]J Neuroimmunol. 2002 Sep; 130(1-2):86-99.
[J Neuroimmunol. 2002]EMBO Rep. 2004 Oct; 5(10):1000-6.
[EMBO Rep. 2004]J Neurochem. 2004 Sep; 90(5):1163-72.
[J Neurochem. 2004]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Neurochem. 2004 Sep; 90(5):1163-72.
[J Neurochem. 2004]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Neurochem. 2004 Feb; 88(3):746-58.
[J Neurochem. 2004]J Neurochem. 2004 Sep; 90(5):1163-72.
[J Neurochem. 2004]Microbes Infect. 2002 Jul; 4(9):903-14.
[Microbes Infect. 2002]Trends Immunol. 2002 Jun; 23(6):301-4.
[Trends Immunol. 2002]Science. 1990 Sep 21; 249(4975):1431-3.
[Science. 1990]Infect Immun. 1996 Jun; 64(6):1906-12.
[Infect Immun. 1996]Cell Mol Life Sci. 2003 Sep; 60(9):1793-804.
[Cell Mol Life Sci. 2003]Microbes Infect. 2002 Jul; 4(9):903-14.
[Microbes Infect. 2002]J Exp Med. 1994 Jan 1; 179(1):269-77.
[J Exp Med. 1994]Immunology. 2004 Oct; 113(2):153-62.
[Immunology. 2004]Annu Rev Immunol. 2003; 21():335-76.
[Annu Rev Immunol. 2003]J Immunol. 1999 Apr 15; 162(8):4801-5.
[J Immunol. 1999]J Neuroimmunol. 2002 Sep; 130(1-2):86-99.
[J Neuroimmunol. 2002]J Neurochem. 2004 Sep; 90(5):1163-72.
[J Neurochem. 2004]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Immunol. 1998 May 1; 160(9):4535-42.
[J Immunol. 1998]J Biol Chem. 1999 Jun 18; 274(25):17406-9.
[J Biol Chem. 1999]J Immunol. 1999 Jul 1; 163(1):1-5.
[J Immunol. 1999]Microbes Infect. 2002 Jul; 4(9):903-14.
[Microbes Infect. 2002]Immunology. 2004 Oct; 113(2):153-62.
[Immunology. 2004]Trends Immunol. 2002 Jun; 23(6):301-4.
[Trends Immunol. 2002]Eur J Immunol. 2005 Apr; 35(4):1201-10.
[Eur J Immunol. 2005]Eur J Immunol. 2005 Mar; 35(3):911-21.
[Eur J Immunol. 2005]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]Infect Immun. 1996 Jun; 64(6):1906-12.
[Infect Immun. 1996]J Biol Chem. 1998 Apr 10; 273(15):8680-90.
[J Biol Chem. 1998]J Exp Med. 1995 Dec 1; 182(6):1673-82.
[J Exp Med. 1995]Blood. 1994 Nov 15; 84(10):3483-93.
[Blood. 1994]Blood. 1996 Mar 1; 87(5):1862-72.
[Blood. 1996]Nature. 2002 Nov 14; 420(6912):182-6.
[Nature. 2002]Vaccine. 2003 Jun 1; 21 Suppl 2():S43-7.
[Vaccine. 2003]Immunity. 2005 May; 22(5):551-60.
[Immunity. 2005]Glia. 2002 Nov; 40(2):195-205.
[Glia. 2002]Infect Immun. 2002 Oct; 70(10):5346-54.
[Infect Immun. 2002]J Immunol. 2001 Apr 15; 166(8):5108-14.
[J Immunol. 2001]Immunol Lett. 2003 Jan 22; 85(2):85-95.
[Immunol Lett. 2003]Biochim Biophys Acta. 2002 Feb 13; 1589(1):1-13.
[Biochim Biophys Acta. 2002]Curr Opin Microbiol. 2004 Feb; 7(1):25-32.
[Curr Opin Microbiol. 2004]Cell Mol Life Sci. 2003 Sep; 60(9):1793-804.
[Cell Mol Life Sci. 2003]Nature. 2000 Dec 7; 408(6813):740-5.
[Nature. 2000]Clin Infect Dis. 1997 Oct; 25(4):763-79; quiz 780-1.
[Clin Infect Dis. 1997]Adv Intern Med. 1998; 43():403-47.
[Adv Intern Med. 1998]J Immunol. 2002 May 15; 168(10):4854-63.
[J Immunol. 2002]J Neuroimmunol. 2002 Sep; 130(1-2):86-99.
[J Neuroimmunol. 2002]J Neurochem. 2001 Nov; 79(3):648-57.
[J Neurochem. 2001]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]J Immunol. 1998 May 1; 160(9):4535-42.
[J Immunol. 1998]J Immunol. 1999 Jul 1; 163(1):1-5.
[J Immunol. 1999]J Immunol. 1999 Apr 15; 162(8):4801-5.
[J Immunol. 1999]Infect Immun. 1993 Oct; 61(10):4452-61.
[Infect Immun. 1993]J Immunol. 1997 May 1; 158(9):4422-9.
[J Immunol. 1997]Microbes Infect. 2004 Dec; 6(15):1368-73.
[Microbes Infect. 2004]Annu Rev Immunol. 2002; 20():825-52.
[Annu Rev Immunol. 2002]J Immunol. 2002 Oct 1; 169(7):3970-7.
[J Immunol. 2002]Nature. 1999 Oct 21; 401(6755):811-5.
[Nature. 1999]J Neuroimmunol. 2002 Sep; 130(1-2):86-99.
[J Neuroimmunol. 2002]Glia. 2005 Mar; 49(4):567-76.
[Glia. 2005]Annu Rev Immunol. 2004; 22():503-29.
[Annu Rev Immunol. 2004]Trends Immunol. 2004 Aug; 25(8):434-40.
[Trends Immunol. 2004]Immunology. 2004 Nov; 113(3):281-92.
[Immunology. 2004]